Minerva Neurosciences宣布融资最高达2亿美元,以推进Roluperidone治疗精神分裂症患者负面症状的三期确认试验,并重新提交新药申请,准备在美国上市(如获批准)。
Minerva Neurosciences宣布融资最高达2亿美元,以推进Roluperidone治疗精神分裂症患者负面症状的三期确认试验,并重新提交新药申请,准备在美国上市(如获批准)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.